Five Key Points For China’s Biopharma Development
This article was originally published in PharmAsia News
A Stanford University scholar recently highlighted five future Chinese biopharma development focuses – medicine invention, promotion of popular drugs, internationalization of sales grids, technology advancement, and state’s nurturing of large businesses.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.